Released Aug 6, 2021, after the close
10-Q filed Aug 9, 2021, 40 days after period end · 0001564590-21-042217
Q2 2021 · 10-Q
Revenue$28.05M$28.05M +196.2% vs Q2 2020+91.3% vs Q1 2021
Net Income-$6.15M-$6.15M N/M vs Q2 2020N/M vs Q1 2021
EPS Diluted-$0.13-$0.13 N/M vs Q2 2020N/M vs Q1 2021
Operating Income-$9,805,000N/M
Operating Cash Flowderived-$5,263,000N/M
Margins · derived
Operating margin-35.0%+138.4 pt vs Q2 2020
Net margin-21.9%
What the release said
The release
Same quarter
| Metric | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 |
|---|---|---|---|---|
| Revenue | $28.05M | $9.47M | $10.53M | $5.70M |
| Net Income | -$6.15M | $29.87M | -$13.79M | -$11.54M |
| EPS Diluted | -$0.13 | $0.94 | -$0.60 | -$24.17 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR